| Name | Title | Contact Details |
|---|
Sebacia is a clinical-stage` private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia’s goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia’s microparticles technology was invented and licensed from Rice University` and the dermatology applications were further developed with researchers from and the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth` Georgia
Canadian Medical Protective Association is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack
Airway Oxygen Inc is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery` diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology` services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65`000 employees have a passion and commitment to help improve patient outcomes` improve the safety and efficiency of clinicians` care delivery process` enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers` BD can help enhance outcomes` lower costs` increase efficiencies` improve safety and expand access to health care. In 2017` BD welcomed C. R. Bard and its products into the BD family.